Cipla receives EIR for Indore plant, Aurbindo for Raleigh

The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)

Everstone acquires controlling stake in Softgel Healthcare

Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

Lonza and Touchlight collaborate on end-to-end mRNA offering

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology

Balaxi Pharma to issue Rs. 49.61 crore Equity Shares/Warrants

Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ

Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise

USFDA completes inspection at Aurolife Pharma’s Raleigh unit

The unit has filed 2 Derma products and 1 MDI product.

ProBioGen enters into master service agreement with NextPoint Therapeutics

The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.

PIB: Quality control of Ayush drugs